Evidence map›Paper›PMID 40183567›Full record

ArticleApplied and environmental microbiology2025

The TetR-like regulator Sco4385 and Crp-like regulator Sco3571 modulate heterologous production of antibiotics in

Sarah Wilcken, Panagiota-Hanna Koutsandrea, Tomke Bakker, Andreas Kulik, Tim Orthwein, Mirita Franz-Wachtel, Theresa Harbig, Kay Katja Nieselt, Karl Forchhammer, Heike Brötz-Oesterhelt and 4 more

Abstract read
In one paragraph

Article in Applied and environmental microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sarah WilckenPharmaceutical Biology, Pharmaceutical Institute, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Panagiota-Hanna KoutsandreaPharmaceutical Biology, Pharmaceutical Institute, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Tomke BakkerPharmaceutical Biology, Pharmaceutical Institute, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Andreas KulikDepartment of Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Tim OrthweinDepartment of Microbiology and Organismic Interactions, Interfaculty Institute of Microbiology and Infection Medicine, Eberhard-Karls-University Tübingen, Tübingen, Germany.ORCID 0000-0002-4650-2554
Mirita Franz-WachtelProteome Center Tübingen, Institute of Cell Biology, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Theresa HarbigInterfaculty Institute for Bioinformatics and Medical Informatics, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Kay Katja NieseltInterfaculty Institute for Bioinformatics and Medical Informatics, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Karl ForchhammerDepartment of Microbiology and Organismic Interactions, Interfaculty Institute of Microbiology and Infection Medicine, Eberhard-Karls-University Tübingen, Tübingen, Germany.ORCID 0000-0003-3199-8101
Heike Brötz-OesterheltPartner Site Tübingen, German Centre for Infection Research (DZIF), Tübingen, Germany.ORCID 0000-0001-9364-1832
Boris MacekProteome Center Tübingen, Institute of Cell Biology, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Silja MordhorstPharmaceutical Biology, Pharmaceutical Institute, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Leonard KaysserInstitute for Drug Discovery, Department of Pharmaceutical Biology, Leipzig University, Leipzig, Germany.ORCID 0000-0002-3943-993X
Bertolt GustPharmaceutical Biology, Pharmaceutical Institute, Eberhard-Karls-University Tübingen, Tübingen, Germany.ORCID 0000-0002-1265-0065

Funding

Deutsche Forschungsgemeinschaft 390838134Deutsche Forschungsgemeinschaft 398967434Deutsche Forschungsgemeinschaft Fo195/921-1Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg (MWK)
6 · The paper itself

Abstract

Heterologous expression in well-studied model strains is a routinely applied method to investigate biosynthetic pathways. Here, we pursue a comparative approach of large-scale DNA-affinity-capturing assays (DACAs) coupled with semi-quantitative mass spectrometry (MS) to identify putative regulatory proteins from

Indexed as

Anti-Bacterial AgentsBacterial ProteinsStreptomyces coelicolorGene Expression Regulation, BacterialMultigene FamilyPromoter Regions, GeneticAnti-Bacterial AgentsBacterial ProteinsCrp regulatorheterologous expressionliponucleoside antibioticsregulation of heterologously expressed antibiotic gene clustersStreptomycesTetR regulator

Identifiers

PMID40183567
PMCPMC12093943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.